Daiichi Sankyo on Monday announced that its Savaysa (edoxaban) tablets are now available in pharmacies across the United States. The drug was granted approval from the Food and Drug Administration on Jan. 8 and is used to reduce the risk of stroke and systemic embolism in patients who have a non-valvular atrial fibrillation, as well as for the treatment of deep vein thrombosis and pulmonary embolism, the company said.
Low-dose aspirin lowers the occurrence of new venous blood clots — and represents a reasonable treatment option for patients who are not candidates for long-term anticoagulant drugs, such as warfarin, according to a new study published in Monday's issue of Circulation.
Beauty company Coty has announced that Georgia May Jagger — supermodel and face of both Coty's color cosmetics brand, Rimmel, and fragrance brand Just Cavalli — has accepted an appointment as the first Coty global ambassador in the fight against blood cancer.
The Food and Drug Administration on Thursday approved Zontivity (vorapaxar) tablets, an anti-platelet agent that's designed to decrease the tendency of platelets to clump together to form a blood clot.
Boehringer Ingelheim Pharmaceuticals announced that the Food and Drug Administration has approved Pradaxa (dabigatran etexilate mesylate), which is used to treat deep venous thrombosis and pulmonary embolism.
Bristol-Myers Squibb Co. and Pfizer announced that the Food and Drug Administration approved a supplemental new drug application for Eliquis (apixaban). The drug is a preventive treatment for deep vein thrombosis, which can lead to pulmonary embolism for patients who have had hip or knee replacement surgery.
Japanese drug maker Daiichi Sankyo is seeking Food and Drug Administration approval for a once-daily tablet to reduce the risk of stroke in patients with atrial fibrillation and treatment of other conditions.
Pharmagen on Thursday announced the launch of Clotamin, a unique multivitamin formulated without vitamin K in order to meet the special nutritional needs of people taking blood-thinning medications (anticoagulants), such as Warfarin.
Reporting their results July 8 in Cancer Cell, researchers say their successful laboratory tests in human MDS cells and mouse models of MDS provide a molecular target for designing new drugs to battle a syndrome with few effective treatments.
The Food and Drug Administration last week approved the anti-clotting drug Eliquis (apixaban), an oral tablet used to reduce the risk of stroke and dangerous blood clots in patients with atrial fibrillation that is not caused by a heart valve problem. Eliquis is manufactured by Bristol-Myers Squibb, and marketed by BMS and Pfizer.
Recent research from the Rothman Institute at Jefferson has shown aspirin to be just as effective in preventing clots — specifically pulmonary emboli, life-threatening blood clots that can develop in the arteries of the lungs following joint replacement surgery — Thomas Jefferson University announced Wednesday.